This article is
- freely available
Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?
Department of Cardiology, Angiology and Pneumology, University of Heidelberg, D-69120 Heidelberg, Germany
Faculty of Medicine, University of Heidelberg, D-69120, Heidelberg, Germany
* Author to whom correspondence should be addressed.
Received: 14 July 2011; in revised form: 17 August 2011 / Accepted: 19 August 2011 / Published: 31 August 2011
Abstract: Epigallocatechin-3-gallate (EGCG), the main and most significant polyphenol in green tea, has shown numerous health promoting effects acting through different pathways, as antioxidant, anti-inflammatory and anti-atherogenic agent, showing gene expression activity, functioning through growth factor-mediated pathways, the mitogen-activated protein kinase-dependent pathway, the ubiquitin/proteasome degradation pathway, as well as eliciting an amyloid protein remodeling activity. However, epidemiological inferences are sometimes conflicting and in vitro and in vivo studies may seem discrepant. Current knowledge on how to enhance bioavailability could be the answer to some of these issues. Furthermore, dose levels, administration frequency and potential side effects remain to be examined.
Keywords: epigallocatechin-3-gallate; green tea; bioavailability
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int. J. Mol. Sci. 2011, 12, 5592-5603.
Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? International Journal of Molecular Sciences. 2011; 12(9):5592-5603.
Mereles, Derliz; Hunstein, Werner. 2011. "Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?" Int. J. Mol. Sci. 12, no. 9: 5592-5603.